First patient dosed in a proof-of-concept study of Yaqrit’s advanced microbiome therapeutic YAQ001 in patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease

Data expected H2 2026Rare liver disease with no approved treatment, typically concurrent with Inflammatory Bowel Disease (IBD)Second YAQ001 clinical study following successful cirrhosis trial LONDON, ...